Pramodini Medicare Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
The capital markets are poised for the arrival of Pramodini Medicare Limited's's Initial Public Offering, targeting a total fundraise of 58,51,200 Shares. This comprises 53,50,800 Shares in new capital generation and ₹5.90 Cr in secondary market transactions through existing shareholders.
Investors can consider participating in this offering within the stipulated price range of ₹110 to ₹118, with each application lot consisting of 1200 shares. The IPO represents a milestone event in the company's corporate journey.
The subscription period commences on Aug 12, 2026 and will remain open until Aug 14, 2026. The basis of allotment will be announced on Aug 17, 2026, with trading expected to initiate on Aug 19, 2026 across the NSE platform.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Pramodini Medicare Limited, incorporated in 2000, is a technology-enabled diagnostic healthcare company providing radiology, clinical laboratory, and nuclear medicine services across India. The company offers a wide range of diagnostic solutions, including MRI, CT scans, X-rays, ultrasound, mammography, pathology, microbiology, biochemistry, PET-CT, SPECT, and nuclear medicine services. It serves government and private hospitals, public sector undertakings (PSUs), medical colleges, and standalone diagnostic centres through multiple partnership models. With a network of diagnostic centres, a 24×7 teleradiology facility, and advanced healthcare technology, Pramodini Medicare focuses on delivering accurate, reliable, and accessible diagnostic services across Tier I, II, and III cities.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Strategic Multi-State Presence: The company operates a network of diagnostic centres across multiple states, serving both government and private healthcare institutions.
- Diversified Business Model: It operates through PPP projects, private hospital partnerships, PSU collaborations, and standalone diagnostic centres, reducing dependence on a single business model.
- Strong Technical & IT Infrastructure: The company uses advanced IT systems to support radiology, laboratory, nuclear medicine, and 24×7 teleradiology services, improving operational efficiency and patient care.
- Dependence on Government PPP Contracts: A significant portion of the company's revenue comes from government PPP projects. Non-renewal of contracts or payment delays could affect business performance.
- High Reliance on Radiology Services: The company earns a large share of its revenue from radiology services. Any slowdown in this segment could impact revenue and profitability.
- Geographical Concentration Risk: A significant portion of the company's revenue comes from Andhra Pradesh. Any adverse developments in this state could affect business operations and financial performance.
- Chalasani Durga Aashritha
- Chalasani Kavitha
- Chalasani Kuldeep Kumar
- Chalasani Lalithakumar
- Sri Ram Medicare Pvt. Ltd.
Pramodini Medicare Limited
Purva Sharegistry India Private Limited